000170965 001__ 170965 000170965 005__ 20260430151736.0 000170965 0247_ $$2doi$$a10.1016/j.ad.2026.104632 000170965 0248_ $$2sideral$$a149038 000170965 037__ $$aART-2026-149038 000170965 041__ $$aeng 000170965 100__ $$0(orcid)0000-0001-8034-3617$$aGilaberte, Y.$$uUniversidad de Zaragoza 000170965 245__ $$aPatient- and Clinician-reported Outcomes, Safety and Efficacy Profile of Tirbanibulin 1% for Actinic Keratosis Under Conditions Close to Routine Clinical Practice in Spain and Italy (TIRBASKIN Study) 000170965 260__ $$c2026 000170965 5060_ $$aAccess copy available to the general public$$fUnrestricted 000170965 5203_ $$aObjective To assess patient- and clinician-reported outcomes, efficacy, and safety of tirbanibulin 1% administered to patients with actinic keratoses (AKs) in Spain and Italy. Methods TIRBASKIN is a multicenter, single-cohort, phase IV, low-interventional clinical study conducted among adults with 4–8 AK lesions on the face or scalp in an area ≤25 cm2. Patients applied tirbanibulin for 5 consecutive days. The primary endpoint was treatment satisfaction on day 57 (D57), assessed with the Treatment Satisfaction Questionnaire for Medication 9 (TSQM-9). Efficacy was assessed by the percentage of patients with complete clearance (CC) and partial clearance (PC) at D57. Tolerability was assessed by local tolerability signs (LTSs), also known as local skin reactions. Results A total of 328 patients (mean age, 74.8 years; male, 83.5%; Fitzpatrick skin type II, 53.7%; AKs on the scalp, 52.7%) completed study assessments at D57. Patients reported high levels of satisfaction with tirbanibulin as assessed by TSQM-9 (effectiveness mean score, 73.6; convenience mean score, 82.8; global satisfaction mean score, 76.9). Moreover, 87.7% of clinicians and 81.8% of patients reported overall satisfaction with tirbanibulin as much/somewhat better compared with previous topical treatment. In addition, 87.1% of clinicians and 86.3% of patients reported a likelihood of reconsidering tirbanibulin in the future, if needed. CC was achieved by 54.3% of patients and PC by 76.2%. At D8, the most frequent LTSs were erythema/redness (mild/moderate, 72.2%; severe, 2.2%) and flaking/scaling (mild/moderate, 34.6%; severe, 0.6%), which had mostly resolved by D57. Conclusions Patients’ and clinicians’ satisfaction was high, and both groups reported a high likelihood of using tirbanibulin again, if needed. 000170965 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es 000170965 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000170965 700__ $$aYélamos, O. 000170965 700__ $$aCañueto, J. 000170965 700__ $$aSerra-Guillén, C. 000170965 700__ $$aConti, A. 000170965 700__ $$aPajuelo, F. 000170965 700__ $$aLecchi, A. 000170965 700__ $$aCappello, V. 000170965 700__ $$aKostov, B. 000170965 700__ $$aPadullés, L. 000170965 700__ $$aRomanelli, M. 000170965 7102_ $$11007$$2183$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cÁrea Dermatología 000170965 773__ $$g117, 7 (2026), 104632 [8 pp.]$$pActas dermo-sifiliogr.$$tActas Dermo-Sifiliograficas$$x0001-7310 000170965 8564_ $$s7453247$$uhttps://zaguan.unizar.es/record/170965/files/texto_completo.pdf$$yVersión publicada 000170965 8564_ $$s2219970$$uhttps://zaguan.unizar.es/record/170965/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000170965 909CO $$ooai:zaguan.unizar.es:170965$$particulos$$pdriver 000170965 951__ $$a2026-04-30-13:58:02 000170965 980__ $$aARTICLE